JP2016508794A - 生体適合性コーティングを有する医用デバイス - Google Patents
生体適合性コーティングを有する医用デバイス Download PDFInfo
- Publication number
- JP2016508794A JP2016508794A JP2015558473A JP2015558473A JP2016508794A JP 2016508794 A JP2016508794 A JP 2016508794A JP 2015558473 A JP2015558473 A JP 2015558473A JP 2015558473 A JP2015558473 A JP 2015558473A JP 2016508794 A JP2016508794 A JP 2016508794A
- Authority
- JP
- Japan
- Prior art keywords
- bisphosphonate
- metal substrate
- coating
- metal
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 66
- 239000011248 coating agent Substances 0.000 title claims abstract description 63
- 229910052751 metal Inorganic materials 0.000 claims abstract description 101
- 239000002184 metal Substances 0.000 claims abstract description 101
- 229940122361 Bisphosphonate Drugs 0.000 claims abstract description 71
- 150000004663 bisphosphonates Chemical class 0.000 claims abstract description 69
- 239000000758 substrate Substances 0.000 claims abstract description 61
- 239000010410 layer Substances 0.000 claims abstract description 25
- 239000002356 single layer Substances 0.000 claims abstract description 13
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000004437 phosphorous atom Chemical group 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 22
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 20
- 238000010438 heat treatment Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 230000006698 induction Effects 0.000 claims description 8
- 229910052698 phosphorus Inorganic materials 0.000 claims description 8
- -1 pyrrolidyl Chemical group 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 210000003709 heart valve Anatomy 0.000 claims description 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 2
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 2
- 229960004343 alendronic acid Drugs 0.000 claims description 2
- 230000000702 anti-platelet effect Effects 0.000 claims description 2
- 230000002965 anti-thrombogenic effect Effects 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229960002286 clodronic acid Drugs 0.000 claims description 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 2
- 229960003978 pamidronic acid Drugs 0.000 claims description 2
- 229960000759 risedronic acid Drugs 0.000 claims description 2
- 229960005324 tiludronic acid Drugs 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 2
- 239000007943 implant Substances 0.000 description 17
- 208000037803 restenosis Diseases 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 230000028709 inflammatory response Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 239000010937 tungsten Substances 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 0 C*C(*)(P(*)(*N)O)P(*)(O)OC Chemical compound C*C(*)(P(*)(*N)O)P(*)(O)OC 0.000 description 1
- 229910000882 Ca alloy Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 229910003271 Ni-Fe Inorganic materials 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- IHBCFWWEZXPPLG-UHFFFAOYSA-N [Ca].[Zn] Chemical compound [Ca].[Zn] IHBCFWWEZXPPLG-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 125000005340 bisphosphate group Chemical group 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005674 electromagnetic induction Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 239000012811 non-conductive material Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/18—Processes for applying liquids or other fluent materials performed by dipping
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D3/00—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
- B05D3/02—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by baking
- B05D3/0218—Pretreatment, e.g. heating the substrate
- B05D3/0236—Pretreatment, e.g. heating the substrate with ovens
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D3/00—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
- B05D3/02—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by baking
- B05D3/0218—Pretreatment, e.g. heating the substrate
- B05D3/0245—Pretreatment, e.g. heating the substrate with induction heating
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/386—Polyphosphonic acids containing hydroxy substituents in the hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
R1は
(i)非置換の又は−NH2、ピリジル、ピロリジルもしくはNR3R4で置換された−C1〜5アルキル、
(ii)−NHR5、
(iii)−SR6、又は
(iv)−Cl
を表し、
R2は−H、−OH、又は−Clを表し、
R3は−H又は−C1〜5アルキルを表し、
R4は−C1〜5アルキルを表し、
R5は−C1〜10アルキル又は−C3〜10シクロアルキルを表し、
R6はフェニルを表す。
(a)金属基材を用意するステップ、
(b)ビスホスホン酸を含む液体キャリアを調製するステップ、
(c)金属基材を液体キャリアに浸漬するステップ、及び
(d)液体キャリア中で金属基材の表面にビスホスホン酸化合物を共有結合で固定化するステップを含み、
ビスホスホン酸に含まれる両方のリン原子が同一の炭素原子に共有結合する方法を提供する。
R1は
(i)非置換の又は−NH2、ピリジル、ピロリジル、もしくはNR3R4で置換された−C1〜5アルキル、
(ii)−NHR5、
(iii)−SR6、又は
(iv)−Cl
を表し、
R2は−H、−OH、又は−Clを表し、
R3は−H又は−C1〜5アルキルを表し、
R4は−C1〜5アルキルを表し、
R5は−C1〜10アルキル又は−C3〜10シクロアルキルを表し、
R6はフェニルを表す。
(コーティングの形成)
コートすべき医用デバイスとして、長さ2cmの5mmPhynoxステントを用意した。オーブン中、15分、550℃の熱処理(TT)によってPhynoxの表面を改質し、次いで化学処理(CT、ステントを0.1%HF及び20%HNO3の溶液に15分浸漬し、次いでステントを2.5%HNO3の溶液に30分浸漬する)を行なった。表面処理の前に、ステントをエチレンオキシド滅菌プロセスに供した。母液(60%v/v)を1000倍に希釈することによってエチドロン酸(EA)水溶液を得た。この溶液にステントを浸漬し、80℃で48時間加熱した。
(誘導加熱)
コートすべき医用デバイスとして、長さ2cmの5mmPhynoxステントを用意した。オーブン中、15分、550℃の熱処理(TT)によってPhynoxの表面を改質し、次いで化学処理(CT、ステントを0.1%HF及び20%HNO3の溶液に15分浸漬し、次いでステントを2.5%HNO3の溶液に30分浸漬する)を行なった。濃度10−3Mのエチドロン酸水溶液を調製した。この溶液にステントを浸漬し、出力110kW、周波数198kHzのAmbrell EasyHeat誘導加熱システムを用いる誘導加熱に供した。用いたソレノイドは、内径9cmの7個のスパイアからなっていた。
(血小板付着)
凝集を防止するため、3.6mlの3.5%クエン酸ナトリウムを含むバイアルに血液を収集した。2種の異なった血漿を得るため、2種の異なった回転速度で全血を遠心分離した。第1の種類(多血小板血漿(PRP))は900rpmの遠心によって得た。第2の種類(乏血小板血漿(PPP))は1500rpmの遠心によって得た。試験のために十分な量を得るため、血漿をHBSS(Hankの緩衝塩溶液)で希釈した。血小板付着は分光光度法によって測定した。全タンパク質量は280nmにおける吸光度の測定によって評価した。実施例1に記載したように未コートの金属ステント及びEAコーティングを行なったステントを調製し、2種の血漿溶液の1つに37℃で24時間、一定の撹拌(STAT−FAX2200 恒温撹拌機)下に浸漬した。完了後、ステントをHBSS緩衝液で洗浄し、次いで125μlの溶解液で処理する。次いで280nmにおける全吸光度を測定する。それぞれの試料の値をそれぞれの実験(PRP及びPPP)の対照の平均値で除することによって、生データを正規化した。
(内皮細胞の増殖:内皮化)
未コート金属ステント及びEAコーティングを有するステントを実施例1に記載したように調製し、ウェルあたり細胞70,000個(EA.hY926)で7日間培養した(37℃、CO25%)。細胞がこのように大量にあることにより、ステントのメッシュの中に細胞がトラップされる確率が高まると考えられた。培養期間中2回(1日後及び4日後)、培地の80%(5ml中4ml)を交換した。完了後、ステントをHBSS緩衝液で洗浄し、次いで125μlの溶解液で処理する。次いで280nmにおける全吸光度を測定する。
(炎症の誘導)
未コート金属ステント及び実施例1に記載したように調製したEAコーティングステントについて得られるIL−8の値を、培地中で通常のELISAセットを用いて、提供された説明書に従って測定した。
Claims (15)
- R1が−CH3を表し、R2が−OHを表す、請求項1に記載の血管内補綴物。
- ビスホスホネートのコーティングの表面リン原子濃度が少なくとも70%P、好ましくは少なくとも80%Pである、請求項1又は2に記載の血管内補綴物。
- ステント、ステントグラフト、フィルター、心臓弁、冠動脈ステント及び末梢ステントからなる群から選択される、請求項1〜3のいずれかに記載の血管内補綴物。
- R1が−CH3を表し、R2が−OHを表す、請求項5に記載の使用のための組成物。
- R1が−CH3を表し、R2が−OHを表す、請求項7に記載の使用のための組成物。
- ビスホスホネート組成物によって金属基材をコーティングするための方法であって、
(a)金属基材を用意するステップ、
(b)一般式(I’)
(c)金属基材を液体キャリアに浸漬するステップ、及び
(d)前記液体キャリア中で金属基材を誘導加熱に供することによって金属基材の表面にビスホスホン酸化合物を共有結合で固定化するステップ
を含み、
R1は(i)非置換の又は−NH2、ピリジル、ピロリジルもしくはNR3R4で置換された−C1〜5アルキル、(ii)−NHR5、(iii)−SR6、又は(iv)−Clを表し、
R2は−H、−OH、又は−Clを表し、
R3は−H又は−C1〜5アルキルを表し、
R4は−C1〜5アルキルを表し、
R5は−C1〜10アルキル又は−C3〜10シクロアルキルを表し、
R6はフェニルを表し、
ビスホスホネート組成物は金属基材の外表面を単層としてかつ最外層として連続的にコートしており、ビスホスホネートの少なくとも1つのホスホネート部分はコーティング中の金属基材の外表面に共有結合で直接結合する、方法。 - 金属基材の表面に共有結合によって固定化されていないビスホスホネート酸化合物を該表面から除去するステップ(e)をさらに含む、請求項11に記載の方法。
- ビスホスホン酸が、1−ヒドロキシエチリデン−1,1−ジホスホン酸(エチドロン酸)、アレンドロン酸、クロドロン酸、パミドロン酸、チルドロン酸及びリセドロン酸からなる群から選択され、好ましくはエチドロン酸である、請求項12に記載の方法。
- コートされる金属基材の表面が、その上に厚い金属酸化物の外層を形成させるために熱処理に供される、請求項11〜13のいずれかに記載の方法。
- 熱処理が、コートされる金属基材を少なくとも10分、好ましくは少なくとも15分、少なくとも500℃、好ましくは少なくとも550℃の温度で加熱するステップを含む、請求項14に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13156274.6 | 2013-02-22 | ||
EP13156274.6A EP2769741A1 (en) | 2013-02-22 | 2013-02-22 | Medical device with a biocompatible coating |
PCT/EP2014/053481 WO2014128280A1 (en) | 2013-02-22 | 2014-02-21 | Medical device with a biocompatible coating |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016508794A true JP2016508794A (ja) | 2016-03-24 |
JP6404238B2 JP6404238B2 (ja) | 2018-10-10 |
Family
ID=47757382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015558473A Active JP6404238B2 (ja) | 2013-02-22 | 2014-02-21 | 生体適合性コーティングを有する医用デバイス |
Country Status (12)
Country | Link |
---|---|
US (2) | US20160000967A1 (ja) |
EP (2) | EP2769741A1 (ja) |
JP (1) | JP6404238B2 (ja) |
KR (1) | KR20150127121A (ja) |
CN (1) | CN105102008B (ja) |
AU (1) | AU2014220636B2 (ja) |
BR (1) | BR112015020023A2 (ja) |
CA (1) | CA2899544A1 (ja) |
EA (1) | EA201500860A1 (ja) |
HK (1) | HK1212635A1 (ja) |
IL (1) | IL240211A0 (ja) |
WO (1) | WO2014128280A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014153487A2 (en) * | 2013-03-21 | 2014-09-25 | Poovey John P | Dental implant system comprising means for preventing rotation of the superstructures and methods of forming and installing |
EP3078350B1 (en) * | 2015-04-09 | 2018-01-31 | Frid Mind Technologies | 3d filter for prevention of stroke |
GB201509693D0 (en) * | 2015-06-04 | 2015-07-22 | Univ Bristol | Orthopaedic and dental material |
MX2018009685A (es) * | 2016-02-12 | 2019-07-08 | Nano Bridging Molecules Sa | Tratamiento mejorado de implantes con compuestos de acido fosfonico. |
US20210199674A1 (en) * | 2019-12-25 | 2021-07-01 | Arkray, Inc. | Treatment method, analyzing device, and surface treating liquid |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030044408A1 (en) * | 2001-06-15 | 2003-03-06 | The Children's Hospital Of Philadelphia | Surface modification for improving biocompatibility |
US20050049693A1 (en) * | 2003-08-25 | 2005-03-03 | Medtronic Vascular Inc. | Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease |
JP2007533345A (ja) * | 2003-08-21 | 2007-11-22 | オプトヴェント・アクチボラゲット | ビスホスホネート被覆インプラントデバイス及びそのための方法 |
JP2007533408A (ja) * | 2004-04-23 | 2007-11-22 | ボストン サイエンティフィック サイムド, インコーポレイテッド | 共有結合的に修飾された生体適合性表面を有する、埋込み可能、又は挿入可能な医用物品 |
US20080011613A1 (en) * | 2004-07-21 | 2008-01-17 | Rizhi Wang | Method of electrolytically depositing a pharmaceutical coating onto a conductive osteal implant |
WO2008017721A2 (fr) * | 2006-08-10 | 2008-02-14 | Surfactis Technologies | Procede de recouvrement de surfaces metalliques ou minerales par des monocouches autoassemblees de composes gem-bisphosphoniques et leurs utilisations |
JP2008521476A (ja) * | 2004-11-26 | 2008-06-26 | ステントミクス・インコーポレイテッド | 化学物質の医療インプラントへのキレート及び結合、作成された医療機器、及び治療への適用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5431920A (en) | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
BE1009278A3 (fr) | 1995-04-12 | 1997-01-07 | Corvita Europ | Tuteur auto-expansible pour dispositif medical a introduire dans une cavite d'un corps, et dispositif medical muni d'un tel tuteur. |
US5891507A (en) | 1997-07-28 | 1999-04-06 | Iowa-India Investments Company Limited | Process for coating a surface of a metallic stent |
JP2002501757A (ja) * | 1998-01-29 | 2002-01-22 | メルク エンド カムパニー インコーポレーテッド | ストレス応答性キナーゼのモジュレーターの特定方法 |
FR2794901B1 (fr) | 1999-06-03 | 2001-07-20 | Framatome Connectors Int | Connecteur de derivation compact d'au moins un cable de derivation sur un cable principal |
WO2007048263A2 (de) * | 2005-10-27 | 2007-05-03 | Nexilis Ag | Implantat und verfahren zu dessen herstellung |
-
2013
- 2013-02-22 EP EP13156274.6A patent/EP2769741A1/en not_active Withdrawn
-
2014
- 2014-02-21 KR KR1020157026111A patent/KR20150127121A/ko not_active Application Discontinuation
- 2014-02-21 WO PCT/EP2014/053481 patent/WO2014128280A1/en active Application Filing
- 2014-02-21 CA CA2899544A patent/CA2899544A1/en not_active Abandoned
- 2014-02-21 AU AU2014220636A patent/AU2014220636B2/en not_active Ceased
- 2014-02-21 CN CN201480008975.7A patent/CN105102008B/zh active Active
- 2014-02-21 EA EA201500860A patent/EA201500860A1/ru unknown
- 2014-02-21 US US14/769,769 patent/US20160000967A1/en not_active Abandoned
- 2014-02-21 EP EP14706549.4A patent/EP2958604B1/en active Active
- 2014-02-21 JP JP2015558473A patent/JP6404238B2/ja active Active
- 2014-02-21 BR BR112015020023A patent/BR112015020023A2/pt not_active Application Discontinuation
-
2015
- 2015-07-29 IL IL240211A patent/IL240211A0/en unknown
-
2016
- 2016-01-15 HK HK16100484.5A patent/HK1212635A1/zh unknown
-
2022
- 2022-03-31 US US17/710,491 patent/US20220218871A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030044408A1 (en) * | 2001-06-15 | 2003-03-06 | The Children's Hospital Of Philadelphia | Surface modification for improving biocompatibility |
JP2007533345A (ja) * | 2003-08-21 | 2007-11-22 | オプトヴェント・アクチボラゲット | ビスホスホネート被覆インプラントデバイス及びそのための方法 |
US20050049693A1 (en) * | 2003-08-25 | 2005-03-03 | Medtronic Vascular Inc. | Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease |
JP2007533408A (ja) * | 2004-04-23 | 2007-11-22 | ボストン サイエンティフィック サイムド, インコーポレイテッド | 共有結合的に修飾された生体適合性表面を有する、埋込み可能、又は挿入可能な医用物品 |
US20080011613A1 (en) * | 2004-07-21 | 2008-01-17 | Rizhi Wang | Method of electrolytically depositing a pharmaceutical coating onto a conductive osteal implant |
JP2008521476A (ja) * | 2004-11-26 | 2008-06-26 | ステントミクス・インコーポレイテッド | 化学物質の医療インプラントへのキレート及び結合、作成された医療機器、及び治療への適用 |
WO2008017721A2 (fr) * | 2006-08-10 | 2008-02-14 | Surfactis Technologies | Procede de recouvrement de surfaces metalliques ou minerales par des monocouches autoassemblees de composes gem-bisphosphoniques et leurs utilisations |
Also Published As
Publication number | Publication date |
---|---|
EP2958604B1 (en) | 2019-08-21 |
BR112015020023A2 (pt) | 2017-07-18 |
JP6404238B2 (ja) | 2018-10-10 |
US20220218871A1 (en) | 2022-07-14 |
AU2014220636B2 (en) | 2017-12-07 |
KR20150127121A (ko) | 2015-11-16 |
CA2899544A1 (en) | 2014-08-28 |
WO2014128280A1 (en) | 2014-08-28 |
EP2958604A1 (en) | 2015-12-30 |
EP2769741A1 (en) | 2014-08-27 |
HK1212635A1 (zh) | 2016-06-17 |
EA201500860A1 (ru) | 2016-02-29 |
US20160000967A1 (en) | 2016-01-07 |
CN105102008A (zh) | 2015-11-25 |
IL240211A0 (en) | 2015-09-24 |
CN105102008B (zh) | 2018-03-27 |
AU2014220636A1 (en) | 2015-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220218871A1 (en) | Medical device with a biocompatible coating | |
Liu et al. | Enhanced in vitro and in vivo performance of Mg–Zn–Y–Nd alloy achieved with APTES pretreatment for drug-eluting vascular stent application | |
Mani et al. | Coronary stents: a materials perspective | |
Palmaz | Intravascular stents: tissue-stent interactions and design considerations. | |
US8697771B2 (en) | Biocompatible coatings, and methods of making and using the same | |
US20100047312A1 (en) | Use of bioactive and radiopaque material for stent coating | |
JP2005510317A (ja) | 生体活性物質を組み入れた金属構造体と、同構造体の製造方法 | |
US20090024211A1 (en) | Stent with a coating or filling of a cavity | |
JP2014521486A (ja) | プラズマ改質医療デバイス及び方法 | |
JP2001309972A (ja) | 生理活性物質が結合された生体適合性医療用金属材料及びその製造方法 | |
Mani et al. | A comprehensive review of biological and materials properties of Tantalum and its alloys | |
CN101883592A (zh) | 涂覆有磷酸钙的包括钴铬合金的支架 | |
US20160256598A1 (en) | Implant having an increased negative surface charger | |
US7955612B1 (en) | Intraluminal device, coating for such device, and method for preparing said device | |
CN110237312A (zh) | 一种可降解的载miRNAs纳米复合涂层及其制备方法和应用 | |
Jurak et al. | Characteristics of Phospholipid–Immunosuppressant–Antioxidant Mixed Langmuir–Blodgett Films | |
CN1694770A (zh) | 包括生物活性材料的金属结构和产生这种金属结构的方法 | |
Yang | Atomic Layer Deposition Coating Titanium Dioxide Nano-thin Film on Magnesium-Zinc Alloy to Enhance Cytocompatibility for Vascular Stents | |
Sinha | In-vitro and in-vivo performance analysis of nitinol as orthopedic implants | |
EP2550033A1 (en) | Bioerodible medical implants | |
Colombo et al. | 7. THE CARBOSTENT SIRIUS STENT | |
Wnek et al. | Surface Coatings/Shih-Horng Su, Suzanne Conroy, Tung-Liang Lin, Min-Shyan Sheu, Ih-Houng Loh | |
Hanawa | 12 Metal–Polymer Composite | |
Wnek et al. | Stents/Benjamin Thierry, Luc Bilodeau, Maryam Tabrizian | |
MXPA06004571A (en) | Method for preparing drug eluting medical devices and devices obtained therefrom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160107 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20160204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160204 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180403 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180706 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180814 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180912 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6404238 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |